Performance of commercial herpes simplex virus type-2 antibody tests using serum samples from Sub-Saharan Africa: A systematic review and meta-analysis

Sexually Transmitted Diseases

Volumn 38, Issue 2, 2011, Pages 140-147

  Biraro, Samuel ^a,b   Mayaud, Philippe ^c   Morrow, Rhoda Ashley ^d   Grosskurth, Heiner ^a,b   Weiss, Helen A ^b  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

AFRICA; ARTICLE; BLOOD SAMPLING; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; GOLD STANDARD; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOASSAY; META ANALYSIS; PUBLICATION; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TASK PERFORMANCE; UNITED STATES; WESTERN BLOTTING;

AFRICA SOUTH OF THE SAHARA; ANTIBODIES, VIRAL; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; UNITED STATES;

EID: 78751648406     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181f0bafb     Document Type: Article

References (37)

1. Malkin JE. Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 2004; 11(suppl 1):2A-23A.
2. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004; 11:24A-35A.
3. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008; 198:1141-1149.
4. Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: Implications for prevention of transmission. J Infect Dis 2008; 198:1098-1100.
5. Corey L, Wald A, Celum CL, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: A review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435-445.
6. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-1571.
7. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: A randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119.
8. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-799.
9. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2 seropositive men: A randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007; 196:1500-1508.
10. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: A randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804-1808.
11. Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008; 49:77-83.
12. Delany S, Mlaba N, Clayton T, et al. Impact of HSV-2 suppressive therapy on genital and plasma HIV-1 RNA in HIV-1 and HSV-2-seropositive women not taking anti-retroviral therapy: A randomized, placebo-controlled trial in Johannesburg, South Africa. AIDS 2009; 23:461-469.
13. Celum C, Wald A, Lingappa J, et al. Twice-daily acyclovir to reduce HIV-1 transmission from HIV-1 / HSV-2 co-infected persons within HIV-1 serodiscordant couples: A randomized, double-blind, placebo-controlled trial 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Cape Town, South Africa. Available at: http://www.ias2009.org/pag/Abstracts.aspx?SID= 2436&AID=3699, 2009.
14. Cowan FM, Johnson AM, Ashley R, et al. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ 1994; 309:1325-1329.
15. Obasi A, Mosha F, Quigley M, et al. Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. J Infect Dis 1999; 179:16-24.
16. Ashley RL. Sorting out the new HSV type specific antibody tests. Sex Transm Infect 2001; 77:232-237.
17. van Dyck E, Buve A, Weiss HA, et al. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Mcrobiol 2004; 42:2961-2965.
18. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-1111.
19. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-973.
20. Vyse AJ, Gay NJ, Slomka MJ, et al. The burden of infection with HSV-1 and HSV-2 in England and Wales: Implications for the changing epidemiology of genital herpes. Sex Transm Infect 2000; 76:183-187.
21. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: A global review. J Infect Dis 2002; 186(suppl 1):S3-S28.
22. Ashley-Morrow R, Nollkamper J, Robinson NJ, et al. Performance of Focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect 2004; 10:530-536.
23. Gamiel JL, Tobian AA, Laeyendecker OB, et al. Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda. Clin Vaccine Immunol 2008; 15:888-890.
24. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927; 22:209-212.
25. Hogrefe W, Su X, Song J, et al. Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera by using recombinant gG2, Western blotting, and gG2 inhibition. J Clin Microbiol 2002; 40:3635-3640.
26. Laeyendecker O, Henson C, Gray RH, et al. Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol 2004; 42:1794-1796.
27. Gorander S, Mbwana J, Lyamuya E, et al. Mature glycoprotein g presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different tanzanian cohorts. Clin Vaccine Immunol 2006; 13:633-639.
28. Ng'ayo MO, Bukusi E, Morrow RA, et al. Sexual and demographic determinants for herpes simplex virus type 2 among fishermen along Lake Victoria, Kenya. Sex Transm Infect 2008; 84:140-142.
29. Smith JS, Bailey RC, Westreich DJ, et al. Herpes simplex virus-type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, Western Blot and inhibition testing. Sex Transm Infect 2009; 85:92-96.
30. Delany S, Jentsch U, Weiss H, et al. Comparison of Focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 (HSV-2) antibodies in a South African population. Sex Transm Infect 2010; 86:46-50.
31. Ashley RL. Performance and use of HSV type-specific serology test kits. Herpes 2002; 9:38-45.
32. Ashley-Morrow R, Krantz E, Wald A. Time course of serocon-version by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis 2003; 30:310-314.
33. Morrow RA, Friedrich D, Krantz E. Performance of the Focus and Kalon enzyme-linked immunosorbent assays for antibodies to herpes simplex virus type 2 glycoprotein G in culture-documented cases of genital herpes. J Clin Microbiol 2003; 41:5212-5214.
34. LeGoff J, Mayaud P, Gresenguet G, et al. Performance of Her-peSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2. J Clin Microbiol 2008; 46:1914-1918.
35. Liljeqvist JA, Svennerholm B, Bergstrom T. Typing of clinical herpes simplex virus type 1 and type 2 isolates with monoclonal antibodies. J Clin Microbiol 1999; 37:2717-2718. (Pubitemid 29337307)
36. Benson DA, Karsch-Mizrachi I, Lipman DJ, et al. Gen Bank. Nucleic Acids Res 2007; 35:D21-D25.
37. Nascimento MC, Ferreira S, Sabino E, et al. Performance of the HerpeSelect (Focus) and Kalon enzyme-linked immunosorbent assays for detection of antibodies against herpes simplex virus type 2 by use of monoclonal antibody-blocking enzyme immu-noassay and clinicovirological reference standards in Brazil. J Clin Microbiol 2007; 45:2309-2311.